Archynetys Live news trend intelligence
◼ Archived Business 🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct

Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says

Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge

By · Published June 25, 2026  02:04 UTC · Updated July 7, 2026  07:01 UTC

9sources
11articles
8velocity
+0%since first seen
126d agofirst detected
Text:
🤖 AI Dossier

Evidence dossier

Intelligence passport

78/100 Excellent
9distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

📍 Aftermath

Definium Therapeutics announced positive topline results from its Phase 3 Emerge study of the DT120 orally disintegrating tablet for major depressive disorder. The LSD-based therapy demonstrated strong antidepressant effects and profound efficacy, which led to a surge in the company's stock price.

Epilogue added 111d ago, after coverage quieted.

How fast it spread

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Where it stands

⚡ Executive Intelligence Takeaways Corroborated across 9 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 9 distinct news outlets with 11 published articles, achieving a live velocity of 8.
  • Primary Driver: Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge
  • Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

Definium Therapeutics has reported positive results from a Phase 3 trial of its LSD-based depression treatment, DT120. The company's CEO described the data as the 'best ever seen' in such a trial.

Coverage from outlets including BioSpace, Yahoo Finance, and Reuters emphasizes the strong efficacy of the drug in treating major depressive disorder. Business Wire reports that Definium will discuss the topline results from the Phase 3 Emerge study.

The next steps involve further analysis of the trial data and potential regulatory submissions. Coverage does not yet specify the timeline for these processes.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 123d ago.

Sources (11)

Answered

What is the name of Definium's LSD-based depression treatment?

The treatment is called DT120.

Which phase of trial has DT120 completed?

DT120 has completed a Phase 3 trial.

What is the stock ticker for Definium Therapeutics?

The stock ticker for Definium Therapeutics is DFTX.

📊 AUDIENCE & LONGEVITY PULSE

How do you expect this trend to evolve over the next 24 hours?

Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.

Select an assessment to vote. Verified Reader Intelligence

Topics

Definium Therapeutics LSD-based therapy depression treatment Phase 3 trial DT120 DFTX

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →